Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
16.07. | Bankrupt Nostrum Labs recalls ulcer drug after shutting down operations | ||
16.07. | Real Chemistry finds its formula, adding a trio of new execs as catalysts for change | ||
16.07. | Amphastar lays out plan to quadruple manufacturing capacity at its California HQ | ||
15.07. | GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment | ||
15.07. | Consumer health giant Kenvue kicks off CEO transition as sales slip | ||
15.07. | As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting | ||
15.07. | As Perrigo's streamlining takes shape, self-care specialist offloads OTC dermatology unit for up to €327M | ||
14.07. | China biotechs 'reshaping' US biopharma as outlicensing deals rise 11%: Jefferies report | ||
14.07. | Humana kicks off virtual brain health challenge ahead of National Senior Games | ||
14.07. | Sun Pharma's alopecia med Leqselvi hits US market after Incyte patent settlement | ||
14.07. | BMS, RayzeBio launch radiopharmaceutical manufacturing site in Indianapolis | ||
14.07. | Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant | ||
14.07. | Ultragenyx takes another hit as FDA snubs AAV gene therapy over manufacturing issues | ||
14.07. | Varda reels in $187M series C to propel drug manufacturing in space | ||
14.07. | Bayer's Kerendia wins FDA label expansion to treat certain patients with heart failure | ||
14.07. | On heels of Gilead deal, Leo pays Boehringer Ingelheim €90 million up front for Spevigo | ||
11.07. | The advantages of lab-based RWD for precise HCP identification | ||
11.07. | Zantac drugmakers notch key win in Delaware as court tosses expert testimony for plaintiffs | ||
11.07. | Karyopharm lays off more workers as hunt for strategic alternatives turns up short | ||
11.07. | Bayer scores first approval for hormone-free menopause drug Lynkuet in UK | ||
11.07. | Jazz hits a sour note in back-to-back rebukes from UK marketing watchdog | ||
11.07. | Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade | ||
11.07. | 'Weak evidence' and an 'unpleasant' odor: FDA sheds light on drug refusal process | ||
10.07. | State AGs unveil opioid settlements totaling $720M with 8 drugmakers | ||
10.07. | Astellas reports 22% sales bump for Izervay, expects trend to continue this year |